Related Experiment Video
Updated: Jun 12, 2025

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2021-2024)
Yung-Fong Tsai1,2, Shun-Chin Yang3, Tsong-Long Hwang1,4,5,6
1Department of Anesthesiology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.
Introduction:
Formyl peptide receptors (FPRs) belong to the family of class A G-protein-coupled receptors that are important for immune modulation and inflammation and are emerging as potential therapeutic targets for several inflammatory diseases. FPRs have shown therapeutic roles in the management of cardiovascular diseases, neuroinflammation, and cancer. Biased agonists are an active topic in the further revisions that encompass the utilization of a definite subset of signaling pathways to improve therapeutic maladies, in parallel with reducing the negative effects.
Areas Covered:
This review surveys the modulators of FPR1 and FPR2 that have been published in patents from 2021 to 2024, to summarize the categorization of agonists and antagonists and discuss their possible clinical uses. A targeted patent search was performed using the Taiwan Patent GO Showcases database (https://tiponet.tipo.gov.tw/gpss/).
Expert Opinion:
We examine newly disclosed patents concerning FPR modulators, with all specified compounds classified as either FPR1 or FPR2 modulators. Receptor cross-reactivity, ligand promiscuity, and receptor variations across species are challenges encountered during drug formulation. Further research into different types of biased agonists and the synthesis of potent and selective ligands is essential to overcome these obstacles and facilitate the eventual therapeutic use of biased signaling in inflammation and diseases.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...

